Calling a study setting a workplace does not make every result an employment outcome. A 2010 lisdexamfetamine trial tested adults in a simulated workplace, with a repeated mathematics measure as its principal outcome.
Who reached the controlled comparison?
The study enrolled 142 adults aged 18–55 with ADHD. They received four weeks of open-label oral lisdexamfetamine optimization, 30–70 mg/day, before a randomized two-week crossover comparing optimized medication with placebo.
There were 127 randomized participants, 105 in the intention-to-treat efficacy population and 103 study completers. The controlled efficacy sample was therefore smaller than both the enrolled and randomized populations. Participants with several psychiatric, substance-use or medical conditions were excluded.
What was measured?
The Permanent Product Measure of Performance, or PERMP, used mathematics problems calibrated to ability. The primary outcome combined problems attempted and correct, averaged across postdose sessions. It was not the number of paid work products completed or a supervisor’s evaluation.
Testing occurred before dosing and from two through 14 hours afterward. The placebo-adjusted least-squares mean difference in average total score was 23.4 points, with a 95% confidence interval of 15.6–31.2. Individual postdose comparisons also favored lisdexamfetamine.
What does the time course establish?
The trial demonstrates a group difference at the sampled times under the protocol. It does not prove that every participant benefited continuously, establish the earliest possible onset or show that effects ended at 14 hours.
Neither PERMP improvement nor ADHD symptom improvement establishes a plasma amphetamine threshold. The study did not validate a concentration-based rule for safe work or driving.
Safety denominators differ again
All 142 enrolled participants contributed to the initial safety population. During optimization, 79.6% reported a treatment-emergent adverse event; appetite reduction, dry mouth, headache and insomnia were prominent. Crossover event rates came from smaller treatment-exposed groups.
A lower event frequency after optimization should be interpreted alongside selection, discontinuation and prior exposure. It does not establish that treatment became harmless once participants entered the blinded phase.
Where does the evidence stop?
The short, industry-sponsored crossover supports improved structured task performance in selected adults with ADHD who reached the randomized phase. It does not independently establish improved employment retention, fewer workplace accidents or better performance in every occupation.
The useful forensic distinction is between a measured laboratory function and the real-world function in dispute. Evidence connecting those functions must be assessed rather than assumed from the study setting’s name.
Scientific source
Wigal T, Brams M, Gasior M, et al. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behavioral and Brain Functions. 2010;6:34. doi:10.1186/1744-9081-6-34. Original commentary on the supplied paper.
Leave a Reply